TetraplegiaPhase 4NCT02379156
Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia
A Phase 4 study testing Midodrine Hydrochloride and Cool Temperature in people with Tetraplegia and Hypothermia, run by James J. Peters Veterans Affairs Medical Center at 1 site in United States.
Trial summary
The ability to maintain normal core body temperature (Tcore = 98.6°F) is impaired in persons with a cervical spinal cord injury (tetraplegia). Despite the known deficits in the ability of persons with spinal cord injury (SCI) to maintain Tcore, and the effects of hypothermia to impair mental function in able-bodied… Read more about this study
- Who is it for?
- Ages 18 to 68 yearsHealthy volunteers can take part
- Conditions the study is for
- Tetraplegia, Hypothermia, Mild Cognitive Impairment
- What is being tested?
- Midodrine Hydrochloride and Cool Temperature
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2015to Dec 2022
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 68 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Duration of SCI ≥1 year;
- Level of SCI C3-T1, AIS A \& B;
- Age between 18 and 68 years.
Who cannot join
- Evidence of sympathetic integrity below the lesion level by the skin axon-reflex vasodilatation (SkARV) test;
- Known allergies to midodrine hydrochloride;
- Past Medical History (PMH) of diagnosed heart, kidney, peripheral vascular, or cerebral vascular disease, or diabetes mellitus;
- Hypertension (BP>140/90 mmHg);
- Untreated thyroid disease;
- Acute illness or infection;
- Current smoker;
- Pregnancy.
Trial locations and contacts
1 site in 1 country.
United States1 site
Center of Excellence for the Medical Consequences of SCI, James J Peters VAMC
The Bronx, New York, 10468
About this study
The ability to maintain normal core body temperature (Tcore = 98.6°F) is impaired in persons with a cervical spinal cord injury (tetraplegia). Despite the known deficits in the ability of persons with spinal cord injury (SCI) to maintain Tcore, and the effects of hypothermia to impair mental function in able-bodied (AB) persons, there has been no work to date addressing these issues in persons with tetraplegia.
Primary Aim: To determine if exposure of up to 2 hours to cool temperatures (64°F) causes Tcore to decrease in persons with tetraplegia, and if that decrease is associated with a decrease in cognitive function.
Read more
Primary Hypotheses: Based on our pilot data: (1) 66% of persons with tetraplegia and none of the matched controls will demonstrate a decline of 1.8°F in Tcore; (2) 80% of persons with tetraplegia and 30% of controls will have a decline of at least one T-score in Stroop Interference scores (a measure of executive function).
Secondary Aim: To determine the change in: (1) distal skin temperature, (2) metabolic rate, and (3) thermal sensitivity.
Secondary Hypothesis: Persons with tetraplegia will have less of a percent change in average distal skin temperatures and metabolic rate, and report lower thermal sensitivity ratings compared with AB controls.
Tertiary Aim: To determine if a 10 mg dose of an approved blood pressure-raising medicine (midodrine hydrochloride) will (1) reduce the decrease in Tcore and (2) prevent or delay the decline in cognitive performance in the group with tetraplegia compared to the exact same procedures performed on the day with no medicine (Visit 1) in that same group.
Tertiary Hypothesis: Through administering a one-time dose of midodrine, the medicine-induced decreased blood flow to the skin will lessen the decline in Tcore and prevent or delay the associated decline in cognitive performance compared to the changes in Tcore and cognitive performance during cool temperature exposure without midodrine in the same group with tetraplegia.
Read the detailed description
This study will investigate the mechanisms contributing to thermoregulatory fragility in persons with tetraplegia when exposed to cool ambient temperatures that are routinely encountered during their activities of daily living (ADL). Subnormal body core temperatures and vulnerability to hypothermia (Tcore<95°F) have been reported in Veterans with tetraplegia upon exposure to relatively mild environmental temperatures. The impact that a drift in Tcore will be expected to have on cognitive performance, specifically working memory and executive function, will be demonstrated. These 2 areas of cognitive performance are vital for the ability to optimally care for one's self, which persons with higher cord lesions must excel at to ensure health and to attain the maximal degree of independence possible. The one-time administration of an alpha agonist, midodrine hydrochloride, in an attempt to attenuate the drift in Tcore and prevent or delay the expected decline in cognitive performance to exposure to cool on cognitive function will be investigated as well.
Preparation for Study Visits:
The study visits will be at least 1 day apart but no more than 2 weeks apart. Subjects will be provided a light, standard meal which they will be asked to eat 2 hours prior to their scheduled visit time. The meal will be either a plain bagel or 2 pieces of toast. For each visit, subjects will be asked to empty their bladders before their arrival and again upon arrival, if needed. Subjects will be asked to avoid caffeinated and alcoholic beverages and heavy exertion for 24-hours before testing. Subjects will wear minimal clothing (gym shorts, sports bra) during the study to maximize bare skin exposure to the cool temperature.
Visit 1: Cold Ambient Challenge Instrumentation: During the subject's first visit, a thin flexible rectal sensor will be placed 4 inches beyond the anal sphincter for Tcore measurement, and skin thermal sensors will be taped at 15 sites above and below the level of lesion for collection of skin temperature (Tsk). A mask will be placed over the subject's nose and mouth for measurement of exhaled gases from which resting metabolic rate will be calculated from analysis of expired gases (VO2) by a metabolic cart. Laser Doppler flowmetry (LDF) will be used to measure changes in microvascular perfusion by taping a laser doppler probe on the skin in the area of the ulnar styloid processes and medial malleoli bilaterally to confirm vasoconstriction. A pulse oximeter will be placed on the left second digit to obtain blood oxygen saturation and heart rate (HR). An automated blood pressure cuff will be placed above the right elbow to measure brachial blood pressure (BP). An intravenous catheter will be placed in the right antecubital or nearby vein and secured for sequential blood collection for blood hormones (cortisol and norepinephrine).
Baseline Collection: At the end of the 30-minute acclimation period (81°F), a 15-minute baseline (BL) collection of the following measures will be performed: Tcore, Tsk, and VO2 will be measured continuously; BP, HR, blood oxygenation, and thermal sensitivity will be measured at 5-minute intervals; 5 minutes of LDF will be measured at 10-minute intervals; a venous blood draw will be collected once for norepinephrine and cortisol concentrations. At the end of the BL period, a cognitive performance battery will be given.
Cool Ambient Challenge: Following the completion of the baseline period, subjects will be wheeled into a 64°F thermal room for 120 minutes or until Tcore ≤ 95°F. Tcore, Tsk, and VO2 will be continuously monitored for safety throughout the study, while BP, HR, blood oxygenation, and thermal sensitivity will be measured every 10 minutes. LDF will be measured for 5 minutes every 25 minutes, and venous blood will be collected every 60 minutes. The cognitive performance battery will be administered when Tcore has declined 1.8°F or is ≤ 95.9°F (in subjects with tetraplegia) or after 120 minutes of cold exposure (in both groups). A decrease in Tcore to ≤ 95°F, or moderate subject discomfort, will result in termination of the protocol. Subjects will be transferred to a warm room (81°F), covered with warming blankets, and given warm fluids. If symptoms continue, Dr. William Bauman will assess the subject and provide the appropriate care.
Visit 2: Cold Ambient Challenge with Midodrine Visit 2 will be completed in the subjects with tetraplegia who participated in Visit 1 and demonstrated an impaired ability to maintain Tcore. All procedures will be conducted in the seated position and will be the same as in Visit 1, with the exception of the oral administration of a 10 mg tablet of midodrine hydrochloride following the completion of the baseline period. Forty minutes after midodrine administration (in order for the medicine's effects to start), a second baseline collection will be performed and subjects will then be placed inside the 64°F thermal room for up to 2 hours or until Tcore ≤ 95°F. Data collection will follow the same schedule and be conducted in the same seated position as in Visit 1. During Visit 2, BP will be continuously monitored after midodrine administration for safety purposes. If subjects' BP increases to 160/90 mmHg, subjects will be seen by Dr. William Bauman, who may consider the administration of labetalol, if necessary.
- Conditions
- Tetraplegia, Hypothermia, Mild Cognitive Impairment
- Being tested
- Midodrine Hydrochloride, Cool Temperature
- Keywords
- Quadriplegia, Spinal Cord Injury, Body Temperature Regulation, Mild Cognitive Impairment
- Medical subject headings
- Quadriplegia, Hypothermia, Cognitive Dysfunction, Spinal Cord Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Midodrine HydrochlorideDrug
Also called Gutron, ProAmatine, Amatine, Orvaten
Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).
Cool TemperatureOther
Also called 64° F
Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).
| Study group | Role | What they receive |
|---|---|---|
| Able-bodied Control Cool Temperature Exposure / No Drug | Other | Subjects are able-bodied (AB) persons, ages 18-65. AB participants were matched to the SCI group by age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1). Receives: Other: Cool Temperature |
| SCI Cool Temperature Exposure / No Drug | Experimental | Subjects are persons with tetraplegia: spinal cord lesion level C3 to T1, American Spinal Injury Association Impairment Scale (AIS) levels A and B, ages 18-65 years. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1). Receives: Other: Cool Temperature |
| SCI Cool Temperature Exposure with Drug | Experimental | Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2). Receives: Drug: Midodrine Hydrochloride; Other: Cool Temperature |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Core Body Temperature
We measured the effects of cool temperature (64°F) exposure, of up to 120 minutes, on the ability to maintain a constant Tcore (i.e., Tcore of 98.6°F) in all intervention arms.
Measured: 120 minutes
Secondary outcomes (4)
Percent Change in Cognitive Performance - Wechsler Adult Intelligence Scale 4th Edition (WAIS IV)
Cognitive performance was assessed using the Wechsler Adult Intelligence Scale 4th Edition (WAIS-IV) Digit Span test, which measures working memory and attention. The test consists of three subtests: Digit Span Forward, Digit Span Backward, and Digit Span Sequencing. Each subtest yields a scaled score ranging from 1 to 19 based on age-based normative data. The total scaled score is obtained by summing the three subtest scores, resulting in a possible total scaled score range of 3 to 57.
For each subtest (Digit Span Forward, Digit Span Backward, and Digit Span Sequencing) and for the total scaled score, higher scores indicate better working memory performance (better outcome), while lower scores indicate poorer working memory performance (worse outcome).
Assessments were conducted at baseline (BL) and after cold ambient exposure. The reported results represent the percent change in each participant's total scaled score from baseline to post-exposure ([(Cold - BL) / BL] × 100).
Measured: 120 minutes
Change in Distal Skin Temperature (Tsk)
We measured the effects of cool ambient exposure (64°F) in each intervention arm by taping 4 thermocouples to the skin of distal areas of the extremities (i.e. the fingers and toes).
Measured: 120 minutes
Percent Change in Microvascular Perfusion
We measured the effects of ambient cool exposure (64°F), for up to 120 minutes, on microvascular perfusion by taping laser doppler flowmetry (LDF) probes to the skin of the hands and feet. LDF was measured in all intervention arms and compared the percent changes in microvascular perfusion within and between groups.
Measured: Up to 120 minutes
Percent Change in Oxygen Consumption (VO2)
We measured the effects of ambient cool exposure (64°F), for up to 120 minutes, on oxygen consumption (VO2) as a measure of resting metabolic rate. VO2 was measured in all intervention arms to compare the percent changes within and between groups.
Measured: Up to 120 minutes.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2015 (estimated)
- Study startApr 2015
- Primary completionJul 2021
- Study completionDec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for TetraplegiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Sponsor type
- US federal agency
- Collaborators
- The Craig H. Neilsen Foundation
- Responsible party
- Principal investigator, John Handrakis, PT, DPT, EdD, James J. Peters Veterans Affairs Medical Center
- Investigators
- John P Handrakis, PT, DPT, EdD, Principal investigator, James J. Peters VAMC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02379156
- Sponsor's protocol ID
- HAN-14-045
- Other IDs
- 315696, 01589
- Status last verified
- Mar 2025
- First submitted
- 26 Feb 2015
- Last updated
- 21 Mar 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia
- ClinicalTrials.gov ID
- NCT02379156
- Acronym / sponsor ID
- HAN-14-045
- Conditions
- Tetraplegia, Hypothermia, Mild Cognitive Impairment
- Keywords
- Quadriplegia, Spinal Cord Injury, Body Temperature Regulation, Mild Cognitive Impairment
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- James J. Peters Veterans Affairs Medical CenterUS federal agency
- Collaborators
- The Craig H. Neilsen Foundation
- Study start
- Apr 2015
- Primary completion
- Jul 2021 (actual)
- Study completion
- Dec 2022 (actual)
- First posted
- 4 Mar 2015 (estimated)
- Results
- Posted 21 Mar 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The ability to maintain normal core body temperature (Tcore = 98.6°F) is impaired in persons with a cervical spinal cord injury (tetraplegia). Despite the known deficits in the ability of persons with spinal cord injury (SCI) to maintain Tcore, and the effects of hypothermia to impair mental function in able-bodied (AB) persons, there has been no work to date addressing these issues in persons with tetraplegia.
Primary Aim: To determine if exposure of up to 2 hours to cool temperatures (64°F) causes Tcore to decrease in persons with tetraplegia, and if that decrease is associated with a decrease in cognitive function.
Primary Hypotheses: Based on our pilot data: (1) 66% of persons with tetraplegia and none of the matched controls will demonstrate a decline of 1.8°F in Tcore; (2) 80% of persons with tetraplegia and 30% of controls will have a decline of at least one T-score in Stroop Interference scores (a measure of executive function).
Secondary Aim: To determine the change in: (1) distal skin temperature, (2) metabolic rate, and (3) thermal sensitivity.
Secondary Hypothesis: Persons with tetraplegia will have less of a percent change in average distal skin temperatures and metabolic rate, and report lower thermal sensitivity ratings compared with AB controls.
Tertiary Aim: To determine if a 10 mg dose of an approved blood pressure-raising medicine (midodrine hydrochloride) will (1) reduce the decrease in Tcore and (2) prevent or delay the decline in cognitive performance in the group with tetraplegia compared to the exact same procedures performed on the day with no medicine (Visit 1) in that same group.
Tertiary Hypothesis: Through administering a one-time dose of midodrine, the medicine-induced decreased blood flow to the skin will lessen the decline in Tcore and prevent or delay the associated decline in cognitive performance compared to the changes in Tcore and cognitive performance during cool temperature exposure without midodrine in the same group with tetraplegia.
Detailed description
This study will investigate the mechanisms contributing to thermoregulatory fragility in persons with tetraplegia when exposed to cool ambient temperatures that are routinely encountered during their activities of daily living (ADL). Subnormal body core temperatures and vulnerability to hypothermia (Tcore<95°F) have been reported in Veterans with tetraplegia upon exposure to relatively mild environmental temperatures. The impact that a drift in Tcore will be expected to have on cognitive performance, specifically working memory and executive function, will be demonstrated. These 2 areas of cognitive performance are vital for the ability to optimally care for one's self, which persons with higher cord lesions must excel at to ensure health and to attain the maximal degree of independence possible. The one-time administration of an alpha agonist, midodrine hydrochloride, in an attempt to attenuate the drift in Tcore and prevent or delay the expected decline in cognitive performance to exposure to cool on cognitive function will be investigated as well.
Preparation for Study Visits:
The study visits will be at least 1 day apart but no more than 2 weeks apart. Subjects will be provided a light, standard meal which they will be asked to eat 2 hours prior to their scheduled visit time. The meal will be either a plain bagel or 2 pieces of toast. For each visit, subjects will be asked to empty their bladders before their arrival and again upon arrival, if needed. Subjects will be asked to avoid caffeinated and alcoholic beverages and heavy exertion for 24-hours before testing. Subjects will wear minimal clothing (gym shorts, sports bra) during the study to maximize bare skin exposure to the cool temperature.
Visit 1: Cold Ambient Challenge Instrumentation: During the subject's first visit, a thin flexible rectal sensor will be placed 4 inches beyond the anal sphincter for Tcore measurement, and skin thermal sensors will be taped at 15 sites above and below the level of lesion for collection of skin temperature (Tsk). A mask will be placed over the subject's nose and mouth for measurement of exhaled gases from which resting metabolic rate will be calculated from analysis of expired gases (VO2) by a metabolic cart. Laser Doppler flowmetry (LDF) will be used to measure changes in microvascular perfusion by taping a laser doppler probe on the skin in the area of the ulnar styloid processes and medial malleoli bilaterally to confirm vasoconstriction. A pulse oximeter will be placed on the left second digit to obtain blood oxygen saturation and heart rate (HR). An automated blood pressure cuff will be placed above the right elbow to measure brachial blood pressure (BP). An intravenous catheter will be placed in the right antecubital or nearby vein and secured for sequential blood collection for blood hormones (cortisol and norepinephrine).
Baseline Collection: At the end of the 30-minute acclimation period (81°F), a 15-minute baseline (BL) collection of the following measures will be performed: Tcore, Tsk, and VO2 will be measured continuously; BP, HR, blood oxygenation, and thermal sensitivity will be measured at 5-minute intervals; 5 minutes of LDF will be measured at 10-minute intervals; a venous blood draw will be collected once for norepinephrine and cortisol concentrations. At the end of the BL period, a cognitive performance battery will be given.
Cool Ambient Challenge: Following the completion of the baseline period, subjects will be wheeled into a 64°F thermal room for 120 minutes or until Tcore ≤ 95°F. Tcore, Tsk, and VO2 will be continuously monitored for safety throughout the study, while BP, HR, blood oxygenation, and thermal sensitivity will be measured every 10 minutes. LDF will be measured for 5 minutes every 25 minutes, and venous blood will be collected every 60 minutes. The cognitive performance battery will be administered when Tcore has declined 1.8°F or is ≤ 95.9°F (in subjects with tetraplegia) or after 120 minutes of cold exposure (in both groups). A decrease in Tcore to ≤ 95°F, or moderate subject discomfort, will result in termination of the protocol. Subjects will be transferred to a warm room (81°F), covered with warming blankets, and given warm fluids. If symptoms continue, Dr. William Bauman will assess the subject and provide the appropriate care.
Visit 2: Cold Ambient Challenge with Midodrine Visit 2 will be completed in the subjects with tetraplegia who participated in Visit 1 and demonstrated an impaired ability to maintain Tcore. All procedures will be conducted in the seated position and will be the same as in Visit 1, with the exception of the oral administration of a 10 mg tablet of midodrine hydrochloride following the completion of the baseline period. Forty minutes after midodrine administration (in order for the medicine's effects to start), a second baseline collection will be performed and subjects will then be placed inside the 64°F thermal room for up to 2 hours or until Tcore ≤ 95°F. Data collection will follow the same schedule and be conducted in the same seated position as in Visit 1. During Visit 2, BP will be continuously monitored after midodrine administration for safety purposes. If subjects' BP increases to 160/90 mmHg, subjects will be seen by Dr. William Bauman, who may consider the administration of labetalol, if necessary.
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Able-bodied Control Cool Temperature Exposure / No Drug | Other | Other: Cool TemperatureSubjects are able-bodied (AB) persons, ages 18-65. AB participants were matched to the SCI group by age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1). |
| SCI Cool Temperature Exposure / No Drug | Experimental | Other: Cool TemperatureSubjects are persons with tetraplegia: spinal cord lesion level C3 to T1, American Spinal Injury Association Impairment Scale (AIS) levels A and B, ages 18-65 years. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1). |
| SCI Cool Temperature Exposure with Drug | Experimental | Drug: Midodrine Hydrochloride, Other: Cool TemperatureSubjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2). |
Who may qualify
- Ages
- 18 to 68 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Duration of SCI ≥1 year;
- Level of SCI C3-T1, AIS A \& B;
- Age between 18 and 68 years.
Key exclusion criteria (8 listed)
- Evidence of sympathetic integrity below the lesion level by the skin axon-reflex vasodilatation (SkARV) test;
- Known allergies to midodrine hydrochloride;
- Past Medical History (PMH) of diagnosed heart, kidney, peripheral vascular, or cerebral vascular disease, or diabetes mellitus;
- Hypertension (BP>140/90 mmHg);
- Untreated thyroid disease;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Midodrine HydrochlorideAlso: Gutron, ProAmatine, Amatine, OrvatenMidodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2). | Drug | SCI Cool Temperature Exposure with Drug |
| Cool TemperatureAlso: 64° FSubjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort). | Other | Able-bodied Control Cool Temperature Exposure / No Drug, SCI Cool Temperature Exposure / No Drug, SCI Cool Temperature Exposure with Drug |
Primary outcome
Change in Core Body Temperature
Time frame: 120 minutes
We measured the effects of cool temperature (64°F) exposure, of up to 120 minutes, on the ability to maintain a constant Tcore (i.e., Tcore of 98.6°F) in all intervention arms.
4 secondary outcomes
Percent Change in Cognitive Performance - Wechsler Adult Intelligence Scale 4th Edition (WAIS IV)
Time frame: 120 minutes
Change in Distal Skin Temperature (Tsk)
Time frame: 120 minutes
Percent Change in Microvascular Perfusion
Time frame: Up to 120 minutes
Percent Change in Oxygen Consumption (VO2)
Time frame: Up to 120 minutes.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Mar 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Link to Research Center website. Look under Research tab to find Thermoregulation program.Link provided by the sponsor.
Related trials for Tetraplegia
Recruiting
MyHand-SCI: An Active Hand Orthosis for Spinal Cord Injury
Spinal Cord Injuries, Tetraplegia
RecruitingPhase 3
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
Chronic Spinal Cord Injury
Recruiting
Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury
Spinal Cord Injury, Acute
Recruiting
Acute Genital Nerve Stimulation for Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury
Fecal Incontinence
RecruitingPhase 2/3
Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)
Spinal Cord Injury, Traumatic Spinal Cord Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John P Handrakis, PT, DPT, EdD principal investigator
James J. Peters VAMC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Midodrine Hydrochloride and Cool Temperature in people with Tetraplegia and Hypothermia, run by James J. Peters Veterans Affairs Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 21 Mar 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Core Body Temperature (time frame: 120 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2025.